melanotan ii mastery course
Unit 4 of 11

chemistry, structure, and pharmacokinetics

a 7-amino-acid cyclic peptide with a half-life that matters

designed for potency, not selectivity

Melanotan II's cyclic heptapeptide structure was engineered for metabolic stability and high receptor binding potency. The lactam bridge that constrains its rigid conformation is the same structural feature that dramatically elevated potency while simultaneously eliminating the receptor selectivity of its linear α-MSH ancestor.

structure comparison tool

compare the structural features of α-MSH, afamelanotide (MT-I), and Melanotan II side by side.

structure comparison tool

structural snapshot

key numbers from MT-II's chemistry and pharmacokinetics.

1024.18 Da
molecular weight -- cyclic heptapeptide, roughly half the size of α-MSH
7 residues
amino acid count -- truncated from α-MSH's 13, retaining only the active core
~30-60 min
plasma half-life (SC injection) -- 10-20x longer than native α-MSH
~100%
subcutaneous bioavailability -- essentially complete systemic absorption
The pharmacokinetic data for MT-II is based on only 3 human subjects from the Dorr 1996 pilot study. No formal PK study has been published. Intranasal PK is completely uncharacterized. The popular nasal spray form delivers roughly 30-40% of the peptide to systemic circulation, but this estimate itself is uncertain.

key terms

structural and pharmacokinetic vocabulary for this unit.

LB lactam bridge structural feature
Covalent amide bond between the gamma-carboxyl of Asp and epsilon-amino of Lys. Constrains 6 of 7 residues into a rigid ring. More chemically stable than disulfide bridges. The source of both MT-II's potency and its non-selectivity.
DP D-Phe7 amino acid substitution
D-phenylalanine replacing L-phenylalanine at position 7. Increases binding affinity and resists proteolytic cleavage at the Phe-Arg bond. One of the two foundational modifications from the NDP-MSH work.
NL Nle4 amino acid substitution
Norleucine replacing methionine at position 4. Prevents oxidation of the methionine sulfur, which would reduce biological activity. The other foundational modification from NDP-MSH.
PH pharmacophore pharmacology
The His-D-Phe-Arg-Trp tetrapeptide sequence -- the minimal active core of α-MSH required for melanocortin receptor activation. MT-II's cyclic structure locks this pharmacophore into an optimal binding conformation.

MT-II chemistry -- the simple version

what Melanotan II actually is, without the jargon.

Melanotan II is a small, lab-made protein fragment built from just 7 amino acids (the building blocks of all proteins). It was designed by taking the natural tanning hormone α-MSH, cutting it in half to keep only the active core, swapping two amino acids to make it harder for enzymes to destroy, and then bending it into a ring shape to lock it into the best possible shape for activating tanning receptors. The ring shape makes it over 1000 times more potent than the natural hormone, but it also makes it activate multiple receptors instead of just the tanning one. That is the core trade-off of its chemistry: the same ring that gives it power takes away its precision.

A advanced: the lactam bridge and conformational constraint term
The ring in MT-II is formed by a lactam bridge -- a covalent amide bond between the side chains of aspartic acid (Asp) and lysine (Lys). This bridge locks six of the seven amino acids into a rigid macrocyclic ring. Unlike disulfide bridges used in many other cyclic peptides, lactam bridges cannot be broken by the body's reducing agents (like glutathione), so MT-II stays in its ring form throughout its entire time in the body. This rigidity pre-organizes the pharmacophore (His-D-Phe-Arg-Trp) into the optimal shape for receptor binding, which is the primary source of MT-II's dramatically increased potency over the flexible, linear α-MSH.
advanced: Nle4 and D-Phe7 substitutions
Two amino acid swaps are critical to MT-II's design. At position 4, methionine is replaced with norleucine (Nle4) -- this prevents oxidation of the sulfur atom in methionine, which would reduce biological activity. At position 7, L-phenylalanine is replaced with its mirror-image form D-phenylalanine (D-Phe7) -- this both increases receptor binding affinity and resists the proteolytic cleavage that normally breaks the Phe-Arg bond. These two modifications were first developed for the linear analog NDP-MSH (Melanotan I) in 1980 and became the foundation for all subsequent melanocortin drug design.
advanced: why cyclization destroys selectivity
Linear peptides like α-MSH and afamelanotide are flexible -- they can fold into different shapes when approaching different receptor subtypes, which allows some degree of selectivity. MT-II's rigid ring presents the same fixed binding surface to all melanocortin receptors equally. The His-D-Phe-Arg-Trp pharmacophore is displayed in one locked conformation that fits MC1R, MC3R, MC4R, and MC5R binding pockets with roughly similar efficiency. This is the fundamental trade-off of cyclization: the same rigidity that maximizes potency eliminates the conformational flexibility needed for receptor discrimination.

pharmacokinetic parameters

what is known (and not known) about MT-II's behavior in the body.

clearance
0.12-0.19 L/kg/h -- predominantly enzymatic degradation, not renal excretion. less than 4% recovered in urine.
BBB penetration
crosses the blood-brain barrier -- confirmed by central MC4R-mediated effects on appetite and sexual function.
intranasal route
~30-40% bioavailability versus SC. never formally characterized. absorption inconsistent, dose control poor.
critical unknowns
no PK in women. no accumulation data. no metabolite profile. no PK in renal/hepatic impairment. based on n=3.